Abstract 946P
Background
Hepatocellular carcinoma (HCC) patients (pts) with major vascular invasion (MVI) or extrahepatic metastases were generally recommended systemic treatment by guidelines, and pts have missed the opportunity for curative resection. Conversion therapy that can convert unresectable HCC into resectable HCC may improve patient survival. Here we report the Sintilimab plus Lenvatini as a conversion therapy for unresectable HCC.
Methods
Briefly, the main inclusion criteria of the study was: Aged 18 to 75 years unresectable HCC pts diagnosed pathologically and/or radiologically, with at least one measurable lesion (mRECIST). The criteria for Successful Conversion: 1. Child-Pugh score < 7. 2. ECOG PS score ≤1. 3. Downstaging to BCLC-A or PR according to mRECIST, and extrahepatic lesions can be resected at the same time. 4. Intact vascular structure of the reserved liver and sufficient FLR.
Results
A total of 137 pts were enrolled in the study by April 10, 2023 and accepted the Sintilimab plus Lenvatinib as conversion therapy,100 pts were finally included for evaluation, in which 58 pts with PVTT (39 pts were classified as VP4), 4 with IVCTT and 7 with both. 26 pts had extrahepatic metastases, and 92 pts were HBV-positive. According to mRECIST, the ORR was 54% and DCR was 77%. Successful conversion rate based on radiology was 51%, and 47% pts received hepatectomy. With a median follow-up of 17 months (range, 1-43), the median OS was 25 months (95% CI, 15.9–34.1) among all pts, the median OS of the pts was not reached [95% CI not reached] in the surgical group and 15 months (95% CI, 10.3–19.7) in the non-surgical group. The median RFS was 25 months (95% CI, 13.6–36.4) in the surgical group and the median PFS was 7 months (95% CI, 3.5–10.5) in the non-surgical group. All pts were evaluable for toxicity, and 83 (83%) pts had at least one treatment-related AE (TRAE). TRAEs occurring in ≥10% of pts were rash (27%), hypertension (18%), hand foot syndrome (17%), and diarrhoea (16%). 28 pts had grade 3 TRAEs.
Conclusions
The combination therapy of Sintilimab plus Lenvatinib can be reviewed as a reasonable and promising conversion therapy option for unresectable HCC with safety and effectiveness.
Clinical trial identification
ChiCTR1900023914.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
832P - Characterisation of EXS73565: A potent and selective MALT1 inhibitor with low drug-drug interaction risk and potential in lymphoma
Presenter: Major Gooyit
Session: Poster session 18
833P - New targets for adult T cell leukemia/lymphoma (ATLL): A map for ATLL immunotherapy
Presenter: Zahra Rezaei Borojerdi
Session: Poster session 18
834P - Phase II clinical study of VR-CAP regimen for first-line treatment of marginal zone lymphoma
Presenter: Junfeng Chu
Session: Poster session 18
835P - A safe and effective immunochemotherapy with oral sobuzoxane and etoposide for untreated diffuse large B cell lymphoma patients aged 80 and over
Presenter: Kaname Miyashita
Session: Poster session 18
838P - Matching-adjusted indirect comparison (MAIC) of axicabtagene ciloleucel (axi-cel) and epcoritamab (epcor) in relapsed/refractory (R/R) large B cell lymphoma (LBCL) after at least two prior systemic therapies (3L+)
Presenter: Olalekan Oluwole
Session: Poster session 18
840P - Genomic landscape, immune characteristics and prognostic mutation signature of extranodal NK/T cell lymphoma, nasal type in China
Presenter: Yue Chai
Session: Poster session 18
841P - Ki67-revised risk index to risk-stratify patients with extra-nodal natural killer/T cell lymphoma
Presenter: Shuo Li
Session: Poster session 18